Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717084 | 0.84 | ATR (0.39) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R2 | |
| SCHEMBL17530833 | 0.83 | CNR1 (0.34) | PIK3CGPIK3CAPIK3CDCNR2 | |
| SCHEMBL716261 | 0.83 | CNR2 (0.36) | CNR2 | |
| SCHEMBL17530768 | 0.82 | HRH4 (0.30) | — | |
| SCHEMBL716760 | 0.82 | HRH4 (0.30) | — | |
| SCHEMBL715850 | 0.77 | ADORA2A (0.34) | PIK3CGCNR2 | |
| SCHEMBL716011 | 0.77 | ADORA2A (0.34) | PIK3CGCNR2 | |
| SCHEMBL864791 | 0.76 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL715667 | 0.75 | CYP1A2 (0.43) | PIK3CGPIK3CDCNR2 | |
| SCHEMBL15875870 | 0.72 | PIK3CB (0.39) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | PIK3CG 28/4885PIK3CA 21/4885PIK3CB 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.